Complix’s proprietary Cell Penetrating Alphabody (CPAB) technology allows it to access a vast diversity of intracellular targets that are considered intractable by current drug formats. Moreover Alphabodies can effectively address therapeutic targets that are hidden in membrane structures or located in tissues that are not easily accessible by conventional antibodies.
Conventional drug formats, such as antibodies or small chemicals, can only address a limited number of all known disease targets. Complix believes that its ability to access a much broader target space, including intracellular targets, with a high affinity protein biologic will allow for the development of an entirely novel class of distinctively competitive therapeutics.
Complix is developing a transformative pipeline of Alphabody therapeutics primarily addressing intracellular disease targets that play an important role in cancer, autoimmunity and viral diseases.
The Company is currently running multiple in-house programs based on selection from a diverse collection of undruggable targets, some of which are being developed in collaboration with partners.
Cell Penetrating Alphabodies are transformative biotherapeutics created to address intracellular targets that are “undruggable” by existing therapeutics…
Complix’s drug development is initially focused on cancer and autoimmune disease, therapeutic areas that represent a significant opportunity for new therapeutic interventions based on addressing intracellular targets.